Development of Personalized Neoantigen Vaccines for Anticancer Immunotherapy

Research Project

Project/Area Number	24K23256
Research Category	Grant-in-Aid for Research Activity Start-up
Allocation Type	Multi-year Fund
Review Section	0801:Pharmaceutical sciences and related fields
Research Institution	Hokkaido University
Principal Investigator	マハモドヨニス北海道大学, 薬学研究院, 特任助教 (60985109)
Project Period (FY)	2024-07-31 – 2026-03-31
Project Status	Granted (Fiscal Year 2024)
Budget Amount *help	¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000) Fiscal Year 2025: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2024: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Keywords	Cancer / Vaccine / mRNA / Lipid nanoparticles
Outline of Research at the Start	In this project, novel, clinically-translatable, personalized anticancer vaccines will be developed using messenger RNA (mRNA) and lipid nanoparticles (LNPs) technologies. LNPs that target the antigen-presenting cells will be used to deliver mRNAs encoding neoantigens to elicit anticancer immunity.